Albumin (as Excipient) Market (Product Type: Human Serum Albumin and Recombinant Albumin; and Application: Human Serum Albumin and Recombinant Albumin)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Albumin as Excipient market size was estimated at USD 0.85 billion in 2021 and is expected to surpass around USD 1.20 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period 2022 to 2030.

Albumin is commonly used in drug formulation, drug delivery, vaccines, and medical device coating. It is also commonly used in diagnostics and in vitro fertilization. Furthermore, it is used as culture medium and stabilizer. Albumin is widely used as a drug carrier in systems such as high albumin globular protein, albumin-drug nanoparticles, and pro-drugs. It is also used as a drug carrier for the treatment of various diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis. Albumin has the ability to bind to an extraordinarily diverse range of molecules, as it provides a depository for various compounds. This renders albumin ideal for usage as an excipient in vaccine and drug production.

Human serum albumin and recombinant albumin are the two types of albumin used as an excipient. Human serum albumin constitutes about 50% of human plasma protein and occurs naturally in the liver. It is proven to be an ideal stabilizer in pharmaceutical and biotech products. It is effective as a drug delivery vehicle, preferred for artificial media, and quite useful in cryopreservation and cell culture. Albumin test checks the albumin level in the blood. Low albumin or high albumin levels indicate issues with liver and kidney. The global albumin (as excipient) market is primarily driven by the increase in usage of albumin as a multifunctional excipient, rise in research & development activities, and launch of new products.

Report Scope of the Albumin as Excipient Market

Increase in Usage of Albumin as Multifunctional Excipient to Drive Global Market

Albumin is a globular protein that is abundant in blood. It is necessary for blood osmotic pressure regulation. It protects globular proteins from oxidation by acting as a powerful antioxidant that prevents protein therapeutics from being modified. Albumin also acts as a blocking agent to prevent non-specific adsorption to glass & plastic surfaces and prevents aggregation of protein products during manufacture and delivery. Albumin has been used as a drug carrier in various systems including albumin fusion proteins, albumin-drug nanoparticles, and pro-drugs. It has also been used as a drug carrier to treat diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis.

Beneficial Properties of Human Serum Albumin to Create Lucrative Opportunities for Market Players

In terms of product type, the human serum albumin segment accounted for significant share of the market in 2021. Human serum albumin (HSA) is a highly stable protein. The stability of albumin makes its handling and storage easier compared to typical globular proteins. The surface-active character of albumin makes it an ideal candidate to be used as a surfactant to prevent protein aggregation. It also has a high glass transition temperature and amphiphilic nature, which makes it an ideal excipient for cryoprotection. Launch of new products by key players is boosting the global market. In May 2020, Bio Products Laboratory (BPL) launched ALBUMINEX 5% and ALBUMINEX 25% for the treatment of hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome (ARDS), and cardiopulmonary bypass.

Significant Usage of Human Serum Albumin Augmenting Drug Delivery Segment

Based on application, the drug delivery segment held major share of the global albumin (as excipient) market in 2021. Human serum albumin is a better carrier in drug delivery systems due to properties such as multiple ligand binding capacity, nontoxicity, and biodegradable non-immunogenic nature. This is likely to propel the segment during the forecast period. The vaccines segment is driven by a shift toward the usage of recombinant albumin among vaccine manufacturers.

Rise in Prevalence of Liver and Kidney Diseases to Drive Pharmaceutical & Biotechnology Industry Segment

In terms of end-user, the pharmaceutical & biotechnology industry segment is projected to account for major share of the global albumin (as excipient) market during the forecast period. Growth of the segment can be ascribed to the increase in demand for advanced medications due to the rise in prevalence of chronic diseases such as liver and kidney diseases. Surge in acceptance of human serum albumin (HSA) and recombinant albumin for drug formulation, vaccine production, and culture media preparation is also anticipated to propel the pharmaceutical & biotechnology industry segment during the forecast period.

Regional Outlook of Global Albumin (as Excipient) Market

North America held the largest share of around 38% of the global albumin (as excipient) market in 2021. It is expected to be a highly lucrative region of the global market during the forecast period. North America's dominance of the global albumin (as excipient) market can be ascribed to the rise in prevalence of major chronic diseases along with the rapid increase in geriatric population in the region. The U.S. dominated the market in North America owing to the increase in demand for albumin in clinical research activities, rise in focus on non-therapeutic applications of albumin, and surge in manufacture of immunoglobulin in the country. Additionally, presence of key players and early adoption of technologically advanced products are projected to drive the market in the country.

Asia Pacific is anticipated to be the fastest growing region of the global albumin (as excipient) market during the forecast period. Aging population, increase in healthcare expenditure, and surge in competition in albumin manufacturing in countries such as China, Japan, and Australia are expected to propel the albumin (as excipient) market in the region.

Analysis of Key Players in Global Albumin (as Excipient) Market

The global albumin (as excipient) market is consolidated, with the presence of a small number of leading players. Most of the companies are investing significantly in research & development activities, primarily to introduce innovative albumin-based products for the treatment of chronic diseases. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players in the global albumin (as excipient) market. Albumedix Ltd., Albumin Therapeutics, LLC (Albumin Bioscience), Biotest AG, CSL Behring (CSL), Grifols, S.A, HiMedia Laboratories, InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA), and Takeda Pharmaceutical Company Limited (Shire) are the key players operating in the global market.

Key Developments in Global Albumin (as Excipient) Market

• In July 2021, Grifols, a global leader in the production of plasma-derived medicines, partnered with the U.S.-based company ImmunoTek Bio Centers LLC to build plasma centers
• In July 2020, Grifols announced an agreement to acquire GC Pharma Group, a biotechnology pioneer in South Korea with a plasma fractionation facility, for around US$ 460 Mn
• In May 2020, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, introduced ALBUMINEX 5 percent (human albumin) solution and ALBUMINEX 25 percent for the treatment of hypovolemia, ascites, and hypoalbuminemia

 Some of the prominent players in the Albumin as Excipient Market include:

• Albumedix Ltd.
• Albumin Therapeutics, LLC (Albumin Bioscience)
• Biotest AG
• CSL Behring (CSL)
• Grifols, S.A.
• HiMedia Laboratories
• InVitria
• Medxbio Pte Ltd.
• Octapharma AG
• RayBiotech, Inc.
• SeraCare Life Sciences
• Sigma-Aldrich Co. (Merck KGaA)
• Takeda Pharmaceutical Company Limited (Shire)

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Albumin as Excipient market

• Product Type
• Human Serum Albumin
• Recombinant Albumin
• Application
• Human Serum Albumin
• Drug Formulation
• Drug Delivery
• Vaccines
• Medical Device Coating
• Culture Medium & Stabilizer
• Diagnostics
• In Vitro Fertilization
• Recombinant Albumin
• Drug Formulation
• Drug Delivery
• Vaccines
• Medical Device Coating
• Culture Medium & Stabilizer
• Diagnostics
• In Vitro Fertilization
• End-user
• Pharmaceutical & Biotechnology Industry
• Research Institutes
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Albumin as Excipient industry analysis from 2022 to 2030 to identify the prevailing Albumin as Excipient industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Albumin as Excipient industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Albumin as Excipient industry trends, key players, market segments, application areas, and market growth strategies.